ABSTRACT-The pharmacological properties of FK 739, a new angiotensin 11-receptor antagonist, were ex amined. FK 739 inhibited the specific binding of [125I1-angiotensin II to rat aortic smooth muscle cell mem brane with an IC50 value of 8.6 nM, but did not displace the specific binding of [1151] -angiotensin II to bovine cerebellum membrane. In isolated helical strips of rabbit aorta, FK 739 shifted the concentration response curve of angiotensin II-induced contraction in parallel to the right, and the values of the slope and pA2 were 1.06 and 8.45, respectively. In in vivo studies, oral administration of FK 739 at 10 mg/kg sig nificantly inhibited the angiotensin I-induced pressor response in normotensive rats and dogs, and it caused a fall of mean blood pressure in renal hypertensive rats and dogs. In spontaneously hypertensive rats, FK 739 at 32 and 100 mg/kg significantly decreased the mean blood pressure in a dose-dependent manner. Additionally, we studied whether FK 739 would cause side effects such as dry cough, like other ACE in hibitors did. Oral administration of FK 739 (10 and 32 mg/kg) did not affect the capsaicin-induced bron chial edema. On the other hand, captopril (10 mg/kg) significantly enhanced capsaicin-induced bronchial edema. These results indicate that FK 739 is a potent and competitive antagonist for AT,-type receptors, and suggest that FK 739 might be a safe and useful agent for the treatment of hypertension in clinical trials.
The renin angiotensin system (RAS) plays an important role in the pathogenesis of hypertension. Angiotensin con verting enzyme (ACE) inhibitors have been used for more than a decade in the clinical treatment of hypertension, and they have also been used with favorable effects on con gestive heart failure (1, 2). However, ACE cleaves not only angiotensin I (Ang I), but also hydrolyzes brady kinin, substance P and enkephalins (3, 4) , so the blockade of ACE may cause side effects such as dry cough (5) . Ac cordingly, selectively preventing the binding of angioten sin II (Ang II) to the receptor would provide a safe and rational way to block the RAS.
Ang II elicits numerous physiological responses such as vasoconstriction, aldosterone release from the adrenal cortex, facilitation of adrenergic neurotransmission and stimulation of the growth of vascular smooth muscle cells (vSMCs) (6 8) . Recently, Ang II receptors have been clas sified into at least two subtypes, AT, and AT2, following the discovery of the nonpeptide Ang II-receptor an tagonists DuP 753 and PD 123319 (9, 10) . The AT, recep tors are located in the rat vSMCs and lung and are also expressed in bovine adrenal medulla, cortex and kidney (11) (12) (13) . AT2 receptors, on the other hand, are detectable in human myometrium and bovine cerebellum (14, 15) . At present, based on the distribution of AT2 receptors, it seems that AT2 receptors do not mainly contribute to the pathogenesis of cardiovascular disease, so a specific AT, receptor antagonist might be preferable for the treatment of hypertension. We used an alternative approach to design a new and potent specific AT,-receptor antagonist and discovered a new nonpeptide Ang II-receptor antagonist, 2-butyl-3 [ {2'-(1H-tetrazol-5-yl)biphenyl-4-yl}methyl]-3H-imidazo [4,5-b] pyridine (FK 739) (Fig. 1) . In this study, we describe the in vitro and in vivo pharmacological profile of the new Ang II-receptor antagonist FK 739.
MATERIALS AND METHODS
Preparation of rat vSMC membrane and bovine cerebel lum membrane for Ang II receptor binding assay Rat vSMCs were obtained from male Wistar rats (7 week-old) using the previously described procedure (16) . Briefly, cells were cultured in Dulbecco's modified Eagle's medium (10% fetal calf serum, 1 % penicillin G and 1 % streptomycin) and used for the binding assay. For the preparation of the vSMC membrane, cells were homog enized in sucrose buffer (50 mM Tris/HCI, 1 mM EDTA and 250 mM sucrose, pH 7.4) of 5 volumes to the wet weight of cells and centrifuged at 1,000 x g for 10 min at 41C. The supernatant was centrifuged at 100,000 x g for 60 min at 4C. After centrifugation, the pellet was sus pended in a small amount of 50 mM Tris/HC1-0.25% bo vine serum albumin buffer (50 mM Tris/HCI and 5 mM MgC12, pH 7.4) and recentrifuged at 100,000 x g for 60 min at 4C. The resulting pellet was resuspended in 50 mM Tris/HC1-0.25% bovine serum albumin buffer (pH 7.4) at a protein concentration of 5 mg/ml and stored at 80'C until used. The prepared vSMC membrane (5 mg protein/ml, 50 p l) was incubated with 0.5 nM [1251]-Ang 11 (50 pl) and vehicle solution or test compounds (50 pl) for 60 min at 25'C in 0.1 ml of Tris/HCl-0.25 % bovine serum albumin buffer. Nonspecific binding was defined as the binding in the presence of 1.0 pM saralasin. After incubation, the reaction was stopped with ice cold 50 mM Tris/HCI buffer. The membrane-bound [1211] -Ang II was separated from free ligand by filtration through a glass filter (GF/B; Whatman, Maidstone, UK). Radioactivity was measured with a gamma counter (Auto-Gamma 5650; Packard, Meriden, CT, USA). Assays were performed in duplicate. IC50 values were determined by the data from two in dependent experiments.
The bovine cerebellum binding assay was performed with an Ang II receptor-drug discovery kit (NED-001; NEN, Boston, MA, USA). The prepared bovine cerebel lum membrane solution (0.2 ml) was incubated with 0.05 nM [1251]-Ang II (0.25 ml) and vehicle or test compounds (10 p1) for 60 min at 371C. Nonspecific binding was defined as the binding in the presence of 1.0 pM saralasin. The reaction was stopped by adding 3 ml of ice cold 0.9% saline. The membrane-bound
[125I]-Ang II was separated from free ligand with a glass filter (GF/B, Whatman). Radioactivity was measured with a gamma counter. As says were performed in duplicate. IC50 values were deter mined by the data from three independent experiments.
Effect on Ang II-induced contractile response in isolated rabbit aorta The descending thoracic aorta was removed from male Japanese white rabbits (2.0-2.5 kg) and cut into helical strips 4 to 5-mm-wide and 20 to 25-mm-long. Each heli cal strip was mounted in a 25-ml tissue bath containing Tyrode's solution (136.9 mM NaCI, 2.7 mM KCI, 1.8 mM CaC12i 1.0 mM MgCI, 11.9 mM NaHCO3, 0.4 mM NaH2PO4 and 5.6 mM dextrose, pH 7.4). The Tyrode's solution was kept at 37 C and bubbled continuously with 5% CO2 in oxygen. Initial resting tension was set at 1.0 g, and the aortic helical strip was allowed to equilibrate for 60 min. At 10 to 15 min intervals, the strip was stimulated by adding 50 mM KCI to the bath and then washed. At the end of the equilibration period, a control cumulative concentration-contractile response curve for Ang II Effect on Ang I-induced pressor response in normotensive rats Male Wistar rats (220-270 g) were used and fasted for 24 hr before this experiment. The animals were anesthe tized with ether. A polyethylene catheter (PE 50) was placed into the right femoral artery for measurement of systemic blood pressure and into the right femoral vein for the dosing of Ang I. After a period of stabilization (about 2.5 hr), the experiment was started. Systemic blood pressure was measured via a pressure transducer (DX-312, Nihon Kohden) in the femoral artery. As the control response, Ang I (0.1 pg/kg) was intravenously injected at 30 min before oral administration of the test compounds. Then the same dose of Ang I was repeatedly injected at 15, 30, 60, 120, 240 and 360 min after adminis tration of the test compounds. Effects of the test com pounds were expressed as the percent change against the control pressor response.
Effect on Ang I-induced pressor response in normotensive dogs
This experiment in conscious normotensive male beagle dogs (8.0 12.0 kg) was carried out with a telemetry sys tem (Multiplus; Primetech, Tokyo). A telemetric transmit ter was implanted in the back of the dog, and its sensing catheter was inserted into the right femoral artery under anesthesia with sodium pentobarbital (35 mg/kg, i.v.). One week after surgery, the animals were fasted for 17 hr before administration of FK 739. Blood pressure and heart rate of the conscious animals were monitored with a receiver (RL2000, Primetech), and when blood pressure and heart rate were stable, Ang I (0.1 pg/kg/min) was in fused for 1 hr to obtain the control response. The vehicle or FK 739 was given orally, and the same dose of Ang I was continuously infused for 6 hr. The data obtained was analyzed with DATEQUEST (Primetech). The effect of FK 739 was expressed as the percent change against the control pressor response.
Effect on blood pressure in renal hypertesive rats (RHRs, 2kidney-1 clip)
Male Wistar rats were anesthetized with sodium pen tobarbital (30 mg/kg, i.p.). The left renal artery was con stricted with a silver clip (internal diameter, 0.22 mm), and the right kidney was left intact. Six weeks after sur gery, the rats were fasted for 24 hr before the experi ments. Under anesthesia with ether, a polyethylene can nula (PE 50) was inserted into the femoral artery for meas urement of blood pressure and plasma renin activity. For measuring the plasma renin activity (PRA), a blood sam ple (1 ml per time point) was collected into a plastic tube containing 50 pl of 50 mM EDTA and was centrifugated at 3,000 x g at 4 C for 20 min to separate the plasma. PRA was estimated enzymatically by measurement of the produced Ang I, which was quantified by a commercially available radioimmunoassay kit (RENIN. RIABEAD; Dainabot, Tokyo). To evaluate the hypotensive activity of the test compounds, experiments were conducted in RHRs with a mean blood pressure of 160-240 mmHg. The vehicle or test compound was given orally. Blood pressure was measured for 6 hr after dosing. Effects of the test compounds on blood pressure were expressed as the percent change against the mean blood pressure under sta ble condition before administration of the test com pounds.
Effect on blood pressure and heart rate in spontaneously hypertensive rats (SHRs) Male SHRs (15 to 18-week-old, 180-250g) with a mean blood pressure of 150-194 mmHg were used after deprivation of food for 24 hr before the experiments. The animals were anesthetized with ether, and a polyethylene cannula (PE 50) was inserted into the femoral artery for measurement of blood pressure. Heart rate was measured with a tachometer (AT-601G, Nihon Kohden) triggered by a pulse wave detector. After a period of stabilization (about 2.5 hr), the vehicle solution or FK 739 was given orally. Effects of FK 739 on blood pressure and heart rate were expressed as the percent change against the mean blood pressure under stable condition before administra tion of the test compounds.
Effect on blood pressure in renal hypertensive dogs (RHDs, 2kidney-1 clip)
Male beagle dogs (8.5 12.5 kg) were used. Under so dium pentobarbital (35 mg/kg, i.v.) anesthesia, left renal blood flow was measured with an electromagnetic flow meter probe (MFV-3200, Nihon Kohden) and reduced to approximately 3007o with a silver clip. A polyethylene tube filled with 3000 U/ml of heparin was inserted into the left femoral artery, and the tip of the tube was left exposed in preparation for measuring blood pressure and heart rate. PRA was determined as described above. Five days later, the cannula tube was connected to a pressure-transducer to measure the blood pressure of the conscious animals. Heart rate was measured with a tachometer (AT-601G, Nihon Kohden) triggered by a pulse wave detector. The experiments were conducted in RHDs with a steady dia stolic pressure of 100 mmHg or more. Vehicle solution or FK 739 was given orally when the blood pressure and heart rate were stable. Effects of the test compounds on blood pressure were expressed as the percent change against mean blood pressure under stable condition before administration of the test compounds.
Effect on the capsaicin-induced bronchial edema Male Hartley guinea pigs (300-350 g) were used. The vehicle solution or test compounds were given orally after depriving the animals of food for 24 hr. One hour later, the animals were anesthetized with sodium pentobarbital (30 mg/kg, i.p.), and a polyethylene cannula (PE 50) was inserted into the right carotid vein. Evans blue dye (20 mg/kg, dissolved in saline) was given intravenously via the cannula tube, and then capsaicin (0.1 mg/kg) was given intravenously. Five minutes later, the bronchia and lungs were excised and perfused with saline. The isolated bronchia was incubated with formamide (4 ml) at 50'C for 24 hr to extract the Evans blue dye. The amount of Evans blue dye was determined by measuring the optical density at 640 nm with a spectrophotometer (U-3200; Hitachi, Tokyo).
Drugs
[125I]-Angiotensin II (specific activity 2200 Ci/mmol) was purchased from DuPont-NEN (Boston, MA, USA). In the rat aortic smooth muscle cell membrane, the binding of [125I]-Ang II was inhibited by saralasin (IC50, 9.1 x 10-9 M) as well as by FK 739 and DuP 753 in a con centration dependent manner. IC50 values of FK 739 and DuP 753 were 8.6 nM and 11 nM, respectively ( Fig. 2A) .
In the bovine cerebellum membrane, saralasin at doses of 0.1 nM or more inhibited the specific binding of [1251] Ang II in a concentration-dependent manner with an IC50 value of 1.4 nM, but FK 739 (1.0 x 10-5 M) and DuP 753 (1.0 x 10-5 M) had no effects (Fig. 2B) .
Inhibition of Ang II-induced the contractile response in rabbit aorta
In rabbit thoracic aorta (Fig. 3A) , Ang 11 (3.2 x 10-10 to 1.0 x 10' M) caused concentration dependent con traction, while FK 739 caused a rightward parallel shift of the concentration response curve of Ang II. Schild analy sis of these data indicated a mean pA2 value of 8.45 and a slope of 1.06 (Fig. 3B) . High concentration of FK 739 (1.0 x 10-6 M) did not change the contractile response curve of norepinephrine (3.2 x 10-'to 10-5 M) or KCl (10 to 50 mM) (data are not shown).
Inhibition of Ang I-induced pressor response in normo tensive rats and dogs
In conscious normotensive rats, the pressor response (25 37 mmHg) was induced by intravenous injection of Ang I (0.1g/kg). Oral administration of FK 739 (10 mg/kg) completely inhibited the Ang I-induced pressor response at 30 min after dosing (from 27 ± 1.0 to 0 ± 0 mmHg, n = 3), and this effect lasted at least 6 hr (Fig. 4A) . Oral administration of DuP 753 also inhibited the pressor response of Ang I (from 25 ±:5.0 to 2.0-L 1.0 mmHg, with the maximal effect at 10 mg/kg, n = 3), and this effect last ed 6 hr (Fig. 4B) . Similarly, captopril inhibited the pres sor response of Ang I (from 37±1.0 to 0±0 mmHg, n=3) (Fig. 4C) .
In conscious normotensive dogs, intravenous infusion of Ang I (0.1 pg/kg/min) caused a stable pressor response (approximately 40 to 50 mmHg). Oral adminis tration of FK 739 (10 mg/kg) completely inhibited the Ang I-induced pressor response at 60 min after dosing (from 53 ± 5 to 0 ± 3 mmHg, n = 3) (Fig. 5 ).
Antihypertensive effect in RHRs, SHRs and RHDs
RHRs: Six weeks after renal artery clipping, PRA was elevated in RHRs (6.4±0.4 ng Ang I/ml/hr in sham oper ated group (n = 3), 38.8 ± 15.2 ng Ang I/ml/hr in renal artery clipping group (n =11)). Under this experimental condition, oral administration of FK 739 (10 or 32 mg/kg) significantly decreased the mean blood pressure in a dose dependent manner (from 218± 12 to 202± 13 mmHg at 10 mg/kg and from 221 ±7 to 159± 11 mmHg at 32 mg/kg, n = 3 4), with the latter effect lasting longer than 6 hr (Fig. 6A) . Oral administration of DuP 753 (10 mg/kg) also decreased the mean blood pressure (from 197 ± 15 to 167±6 mmHg, n=3); and at a dose of 32 mg/kg, it sig nificantly decreased the mean blood pressure for 6 hr af ter dosing (from 221 ± 13 to 158±24 mmHg, n=4) (Fig.  6B ). Captopril (10 or 32 mg/kg) also elicited a significant antihypertensive effect (from 205 ± 7 to 169 ± 9 mmHg, n=4), although it was short lived when compared with that of the same doses of FK 739 or DuP 753 (Fig. 6C) . SHRs: Oral administration of FK 739 decreased the mean blood pressure in a dose-dependent manner for 6 hr after dosing (from 166±2 to 143±7 mmHg at 32 mg/kg and from 176 ± 5 to 144 _±:6 mmHg at 100 mg/kg, n = 6), but did not significantly change the heart rate (from 390±28 to 434±20 beats/min in maximal change, n = 5 6) (Fig. 7, A and B) .
RHDs: PRA and mean blood pressure rose rapidly at 3 days after renal artery clipping and were sustained for 7 days (PRA: 1.9±0.6 ng Ang I/ml/hr at day 0, 12.4±4.4 ng Ang I/ml/hr at day 3 and 7.3 ± 3.5 ng Ang I/ml/hr at day 7; mean blood pressure: 87±2 mmHg at day 0, 135±9 mmHg at day 3 and 125±9 mmHg at day 7, n = 5). To reduce the influence of surgical stress on this ex periment, for all animals, we evaluated the antihyperten sive effect of FK 739 at 5 days after surgery. Oral adminis tration of FK 739 (3.2 mg/kg) significantly decreased the mean blood pressure, and there was a rapid onset of the hypertensive effect of FK 739 after dosing (from 121-L1 to 113 ±4 mmHg at 1.0 mg/kg, from 129----L9 to 100± 10 mmHg at 3.2 mg/kg, n=3-4) (Fig. 8) . Effect on capsaicin-induced bronchial edema As shown in Fig. 9 , the amount of the Evans blue dye was 1.21 ±0.23 pg/g tissue in the bronchia of guinea pigs in the vehicle treatment group (n=8), and that in the FK 739 oral administration groups (10 mg/kg, n=9 or 32 mg/kg, n=3) was almost the same (1.08±0.24 ug/g tis sue at 10 mg/kg and 1.04±0.20 pg/g tissue at 32 mg/kg). On the other hand, captopril (10 mg/kg) significantly in creased the extravasation of Evans blue dye in the bron chia at 2.53 ± 0.24 ng/g tissue (n = 7).
DISCUSSION
Our study clearly showed that FK 739 is a potent, selec tive and competitive antagonist for the AT, receptor. To evaluate the selectivity of FK 739 for the subtypes of Ang II receptors, we used rat aortic smooth muscle cell mem brane as the source of AT,-type receptor and bovine cere bellum membrane as the source of AT2-type receptor. In rat aortic smooth muscle cell membrane, FK 739 dis These results indicate that FK 739 possesses a high selec tive affinity for DuP 753-sensitive Ang II receptor, name ly the AT,-type receptor. In isolated rabbit aorta, FK 739 caused a rightward parallel shift of the concentration response curve of Ang II with a pA2 value of 8.5 and the slope of the Schild plot was 1.06. This result indicates that FK 739 is a competitive antagonist for Ang II receptor. Furthermore, FK 739 itself did not show any contractile response in the isolated rabbit aorta at the highest concen tration of 100 nM and also did not induce the pressor response in conscious normotensive rats, indicating a lack of agonistic activity for the Ang II receptor.
To evaluate the antihypertensive activity of FK 739, we used RHRs and SHRs. In RHRs, oral administration of FK 739 decreased the blood pressure in a dose-dependent manner for at least 6 hr, and the antihypertensive activity of FK 739 was almost the same as that of DuP 753, which had a more profound antihypertensive effect than cap topril. Several studies have also demonstrated the im portant role of RAS in maintaing vascular tone (18 20) . Mizuno et al. reported that captopril could not complete ly inhibit the formation of immunoreactive Ang 11 (21) . This might explain the difference between the antihyper tensive effects of FK 739 and DuP 753 in comparison with that of captopril in RHRs. In SHRs, moreover, oral ad ministration of FK 739 decreased blood pressure in a dose-dependent manner without changing the heart rate, which indicates that this Ang II-receptor antagonist is use ful for treating hypertensive patients with normal renin activity as well as ACE inhibitors, although the qualita tive defferences between the antihypertensive effects of Ang II antagonist and ACE inhibitors have not been fully elucidated.
To ascertain the Ang II-receptor antagonism of FK 739 in different species, we used Ang I-infused hypertensive dogs and RHDs. Intravenous infusion of Ang I produced a stable pressor response in conscious normotensive dogs. Oral administration of FK 739 completely inhibited the Ang I-induced pressor response for 1 hr after dosing. Moreover, in RHDs, oral administration of FK 739 also decreased the mean arterial pressure in a dose-dependent manner. These results show that there is no species differ ence in the pharmacological characteristics of FK 739. In normotensive dogs, FK 739 was almost completely ab sorbed after oral administration, and we could not detect any active metabolites of FK 739 in either rats or dogs (data not shown). On the other hand, DuP 753 is metabo lized to the noncompetitive Ang II-receptor antagonist EXP 3174 which contributes to the long lasting antihyper tensive effect of this compound in RHRs (22) . This meta bolic change may work against its clinical usefulness in patients with impaired renal or hepatic function.
In the clinical application of ACE inhibitors, one well known side effect is persistent dry cough (23) . The mecha nisms of dry cough after treatment with these inhibitors is associated with the increase of bradykinin, substance P and other bronchoconstrictor substances, and it has been reported that captopril potentiates the bronchoconstric tion induced by exogenous bradykinin and substance P in guinea pigs (5) . In this study, the effect of FK 739 on cap saicin-induced bronchial edema in guinea pigs was eval uated and compared with that of captopril. We chose this animal model based on the fact that capsaicin mainly releases bronchoconstrictors such as substance P and bradykinin (24) ; and furthermore, both enalapril and remipril increase the cough reflex response to inhaled cap saicin in hypertensive patients (25) . Oral administration of captopril significantly enhanced capsaicin-induced bronchial edema. On the contrary, oral administration of FK 739 did not show any effect on the capsaicin induced bronchial edema. These results suggest that this new Ang II-receptor antagonist would not increase the sensitivity of the cough reflex and not cause symptoms such as those observed in patients treated with ACE inhibitor.
In conclusion, the present study showed that FK 739 is a potent and selective AT,-receptor antagonist. FK 739 showed sufficient and long lasting antihypertensive activ ity without tachycardia in various hypertensive animal models and species. FK 739 should prove to be a safe and useful agent for the treatment of hypertension in clinical trials.
